Arthrosi, a San Diego-based biotechnology company, raised $153M in Series E funding led by Prime Eight Capital to expand operations and development efforts.

Oct 08, 2025•2 months ago

Amount Raised

$153 Million

Round Type

series e

San DiegoBiotechnologyHealthcare

Investors

Reliant Tech LimitedHm Venture PartnersHigh Light CapitalCr BiotechPrime Eight Capital Limited

Description

Arthrosi raised $153M in Series E funding to support its development of URAT1 inhibitors. The round was led by Prime Eight Capital with participation from several investors. The company is focused on advancing pozdeutinurad in a pivotal Phase 3 program. This funding will help to expand operations and enhance development efforts.

Company Information

Company

Arthrosi Therapeutics

Location

9855 Towne Centre Dr, #200

San Diego, California, United States

About

Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends